Nightstar announces $35 million Series B financing round
NightstaRx Ltd, a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, announces a $35 million Series B financing round. The round was led by New Enterprise Associates, one of the world's leading venture capital firms.